Polymorphisms of the thiopurine S-methyltransferase gene among the Libyan population by Zeglam, HB et al.
ORIGINAL ARTICLE
Polymorphisms of the thiopurine S-methyltransferase
gene among the Libyan population
Hamza Ben Zeglam1, Abdrazak Benhamer1, Adel Aboud1, Haitem Rtemi1,
Meftah Mattardi1, Saleh Suleiman Saleh1, Abdullah Bashein2 and
Nabil Enattah1*
1Department of Genetic Engineering, Biotechnology Research Center (BTRC), Twisha, Tripoli, Libya;
2Department of Biochemistry, Faculty of Medicine, University of Tripoli, Tripoli, Libya
Background: Thiopurine S-methyltransferase (TPMT) is a cytosolic enzyme that catalyses the S-methylation
of 6-mercaptopurine and azathioprine. Low activity phenotypes are correlated with polymorphism in the
TPMT gene. Patients with low or undetectable TMPT activity could develop severe myelosuppression
when they are treated with standard doses of thiopurine drugs. Since ethnic differences in the TPMT gene
polymorphism have been demonstrated worldwide, assessing it in the Libyan population is worthwhile.
Methods: We investigated TPMT gene polymorphism in a total of 246 Libyan healthy adult blood donors
from three different Libyan regions (Tripoli, Yefren, and Tawargha) and 50 children with acute lymphoblastic
leukaemia (ALL). We used polymerase chain reaction restriction length polymorphism (PCR-RFLP) and
allele-specific PCR-based assays to analyse the TPMT gene for the variants *2 c.238 GC, *3A (c.460 GA
and c.719 AG), *3B (c.460 GA), and *3C (c.719 AG).
Results: Our results show that the TPMT variants associated with low enzymatic activity were detected
in 3.25% (8 in 246) of adult Libyan individuals and the frequency of total mutant alleles was 1.63%.
Heterozygous genotypes were TPMT*3A in three subjects (0.61%) and TPMT*3C in five subjects (1.02%).
No TPMT*2 and TPMT*3B allelic variants and no homozygous or compound heterozygous mutant alleles
were detected. The normal allele (wild-type) was found in 98.4% of the adult individuals studied. No mutant
alleles were detected among the 50 children who had ALL.
Conclusions: We report on the presence of the TPMT*3C and *3A mutant alleles in the Libyan population.
Therefore, monitoring the patients to be treated with doses of thiopurine drugs for TPMT variants is
worthwhile to avoid the development of severe myelosuppression.
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T
hiopurine S-methyltransferase (TPMT, EC2. 1.1.67)
is a cytoplasmic enzyme that preferentially cata-
lyses the S-methylation of aromatic and hetero-
cyclic sulfhydryl compounds. This enzyme is responsible
for the inactivation of antimetabolite thiopurine drugs,
such as 6-mercaptopurine, 6-thioguanine, and azathiopr-
ine (1). TPMT is expressed in many cells, with the highest
levels in the liver and the lowest levels in the brain and
lungs (2, 3). Thiopurine drugs have been widely used in
the treatment of leukaemia, autoimmune disorders, and
organ transplants. However, these drugs, like many cyto-
toxic agents, have a relatively narrow therapeutic index,
with the potential for life-threatening drug-induced toxi-
city, primarily myelosuppression (4, 5).
Individual differences in thiopurine drug metabolism,
response, and toxicity in humans have been correlated
with polymorphism of the TPMT gene. The TPMT gene
is localised to chromosome 6p22.3 and is encoded by a
34-kb gene consisting of ten exons and nine introns with
a cDNA of 3,000 bp and an open reading frame of
735 bp that encodes for a 245-amino acid peptide with
a molecular mass of 35 kDa (6). TPMT activity is
inherited as an autosomal co-dominant trait with large
inherited variations in human tissue TPMT enzyme acti-
vity ranging from high to virtually undetectable levels of
activity (1, 7).
Approximately 0.5% of Caucasians exhibit complete
TPMT deficiency correlating with two mutated TPMT
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alleles (homozygote or compound heterozygote), and
about 11% of the population reveal intermediate activity
with the presence of one mutant allele (heterozygote) (8).
Altered TPMT activity predominantly results from
single nucleotide polymorphisms. The wild-type allele
is designated as TPMT*1 and three alleles designated
as TPMT*2 (c.238 GC), TPMT*3A (c.460 GA &
c.719 AG) (9), and TPMT*3C (c.719 AG) (Fig. 1)
account for about 95% of intermediate or low enzyme
activity cases (1115). All these three alleles are asso-
ciated with lower enzyme activity due to increased rates
of proteolysis of the mutant proteins (16). Because of the
clinical importance of TPMT pharmacogenetics, pro-
spective determination of TPMT activity in red blood
cells (RBC) is emerging as a standard clinical test prior to
therapy (17), where identification of the TPMT mutant
alleles allows physicians to tailor the dosage of the
thiopurine drugs to the genotype of the patient or to
use alternatives, improving therapeutic outcome. To date,
more than 28 variant alleles of the TPMT gene have been
reported. There is a large interindividual variability in the
activity of TPMT. Caucasians show a trimodal distribu-
tion, with 8994% possessing high enzymatic activity, 6
11% intermediate activity due to heterozygosity at the
TPMT locus and 0.33% low activity (18). There appear to
be some gender differences in TPMT activity (1921).
The pattern and frequency of mutant TPMT alleles
are different among various ethnic populations (22).
The most prevalent TPMT mutant allele in the Caucasian
and Latin American populations is TPMT*3A, which con-
tains two nucleotide transition mutations (c. 460 GA
and c.719 AG) in the open reading frame, leading to
amino acid substitutions at codon 154 (Ala0Thr) and
codon 240 (Tyr0Cys) (14, 2326), while TPMT*3C
(c.719 AG), which includes only the codon 240
(Tyr0Cys), is predominant in East Asia and among
Egyptians and African Americans (2729).
Unlike TPMT phenotyping, genotyping is not af-
fected by blood transfusion, less affected by pre-analytical
factors, and unaffected by disease activity and drugs.
Restriction digestion is a popular method because it is
easy to perform and requires only basic equipment.
Screening the whole TPMT gene for all 29 different
alleles routinely would be technically demanding and
time-consuming. Moreover, it has yet to be demonstrated
whether some variant alleles result in deficient TPMT
activity (14, 2326). Since TPMT*2, TPMT*3A, and
TPMT*3C make up between 60 and 95% of mutant alleles
resulting in deficient TPMT activity in most populations
(2729), TPMT genotyping is usually performed only
for these mutations. Consequently, patients with new muta-
tions or from certain ethnic populations with rare TPMT
variant alleles may be missed.
In this study, we used restriction fragment length
polymorphism assays (RFLP-PCR) to investigate in
the Libyan population the major mutant alleles of the
Fig. 1. The wild type and the main common mutant alleles. TPMT*1 is the most common allele (wild type), while TPMT*3A
is the most common variant allele in Caucasians and TPMT*3C is the most common variant allele in East Asians. Open
rectangles represent open reading frames (ORF) while the blue rectangles represent 5?- and 3?-untranslated regions (UTR).
Adapted from (10).
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TPMT gene: TPMT*2 (c.238 GC), TPMT*3A (c.460
GA and c.719 AG), TPMT*B (c.460 GA), and
TPMT*3C (c.719 AG) and compared the results with
those published for other ethnic groups.
Materials and methods
All the chemicals used in this study were of molecular
grade. The primers were purchased from Sigma-Proligo;
the sequences of the primers were designed as pre-
viously described (14, 30), except primer P719NF, which
we designed. The primer sequences, annealing tempera-
tures and the sizes of polymerase chain reaction (PCR)
products are listed in Table 1.
Study population
Blood samples were obtained from 246 Libyan volunteers
and 50 Libyan children who had acute lymphoblastic
leukaemia (ALL). Informed consent was obtained from
all the participants or their guardians. The volunteers
enrolled in this study were unrelated blood donors of
different ages, sexes, and Libyan origins. The children
were being treated at the Tripoli Medical Centre (TMC) or
had been referred for evaluation because they could not
tolerate chemotherapy. The TPMT genotype was deter-
mined in 126 females and 170 males. Blood samples of
15 ml were collected in Vacutainer tubes with EDTA
as anticoagulant, transported to the laboratory of the
Genetic Engineering Department at the Biotechnology
Research Centre in Tripoli, and frozen at 208C until
needed for DNA extraction and subsequent PCR analy-
sis. The blood samples from volunteers were collected
from the TMC, Tripoli Central Hospital, Aljla Hospital,
Yefren Hospital, and Tawargha Hospital over a period
of 5 months. The study population was also subdivided
into three main groups: 1) Yefren population, who are of
Amazigh origin and white complexion; 2) Tawargha popula-
tion, who are of African origin and black complexion; and 3)
Tripoli population, which includes Libyans from different
origins, including Yefren and Tawargha, and both white or
black complexion. The Libyan nationality and ethnicityof all
volunteers and children were confirmed by the participants’
self-declaration of race and its agreement with skin colour
and officially registered identity information.
DNA extraction
The method used for DNA extraction and determination
of DNA quantity and quality was according to Sambrook
et al. (31). To determine that the DNA samples extracted
from this procedure were suitable for PCR reaction, they
were analysed by agarose gel electrophoresis.
Polymerase chain reaction
The total number of 296 DNA samples extracted were
suitable for the PCR. Samples had DNA concentrations
of 35565 mg/ml. The optimum concentration for PCR is
250 mg/ml, and for this reason some DNA samples were
diluted.
Three sites of known TPMT gene mutations caus-
ing TPMT deficiency (c.238 GC, c.460 GA, and
c.719AG) were determined according to the method
described by Yates et al. (14), with minor modifications.
In brief, allele-specific PCR amplification was used to
detect the c.238 GC transversion in exon 5, while
PCR amplification and restriction enzyme digestion
(PCR-RFLP) were used to detect the c.460 GA and
c.719 AG mutations in exon 7 and 10, respectively.
Care was taken when PCR primers for TPMT gene
analysis were designed owing to the presence of an inactive
TPMT pseudogene located on chromosome 18, which
has 96% homology to the TPMT gene (32). Since this
inactive TPMT pseudogene is intronless, ensuring that at
least one primer is complementary to the TPMT intron
sequence overcomes this potential interference.
Detection of c.238 GC (TPMT*2 Mutation)
An allele-specific PCR was used to determine whether the
c.238 GC transversion was present at the TPMT locus.
The final volume for all PCR assays was 25 ml in which
genomic DNA (200250 ng) was amplified with 0.9 ml
of 20 mM primer P2C (reverse) and either P2W or P2M
(forward) were used in the wild-type specific or mutant-
type specific reactions, respectively. The reaction included
0.125 ml of Go Taq† Flexi DNA Polymerase, 5 ml 5X
Table 1. Primers used to detect major mutations in the TPMT gene
Exon Primer Sequence (5?3?) Length of product (bp) Annealing temperature (8C)
5 P2W 5? GTATGATTTTATGCAGGTTTG 254 58
5 P2M 5? GTATGATTTTATGCAGGTTTC 254 58
5 P2C 5? TAAATAGGAACCATCGGACAC 254 58
7 P460F 5? ATAACAGAGTGGGGAGGCTGC 365 55
7 P460R 5? CTAGAACCCAGAAAAAGTATAG 365 55
10 P719NF 5? GTTACTCTTTCTTGTTTCAGG 181 58
10 P719R 5? TCCTCAAAAACATGTCAGTGTG 181 58
The primers were adapted from (13, 30), except primer P719NF, which was designed for this study.
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Green Go Taq† Flexi Buffer (Promega), 4 ml 25 mM
MgCl2 solution and 0.5 ml 10 mM dNTP. An Applied
Biosystems thermocycler was used.
PCR amplification consisted of an initial denatura-
tion step at 958C for 2 min followed by 35 cycles of
denaturation at 958C for 40 s, annealing at 578C for 30 s
and extension at 728C for 35 s. The final extension step was
728C for 7 min. Unpurified PCR products were analysed
by electrophoresis in 2.5% agarose gel and stained with
ethidium bromide. A DNA fragment was amplified with
P2M and P2C primers when C238 (mutant) was present,
whereas a DNA fragment was amplified with P2W and
P2C primers when G238 (wild-type) was present (Fig. 2).
Detection of c460 GA (TPMT*3A & TPMT*3B mutations)
To detect the c.460 GA mutation, a PCR assay using
0.9 ml primers (20 mM) P460F and P460R per reaction
tube. The conditions were similar to those mentioned
above, except that 5X Colorless Go Taq† Flexi Buffer
(Promega) was used instead of 5X Green Go Taq† Flexi
Buffer (Promega) and annealing was at 548C for 30 s. The
PCR product containing the fragments of 365 bp was
checked in 2.5% agarose gel, and about 20 ml of PCR
products were purified using the ethanol precipitation
technique (31). The, 7 ml of each purified PCR product
was digested with 0.3 ml of MwoI 5,000 U/ml (New
England BioLabs) in 10.7 ml double-distilled H2O and
2 ml buffer 3 supplied by the manufacturer (100 mM
NaCl, 50 mM Tris-HCl, 10 mM MgCl2, 1 mM dithio-
threitol, pH 7.9) for 2 h at 608C. Digested samples were
electrophoresed in 2.5% agarose gel and stained with
ethidium bromide. MwoI digestion of wild-type DNA
yields fragments of 267 and 98 base pairs, whereas DNA
containing the c.460 GA mutation is not digested and
yields an uncleaved fragment of 365 base pairs (Fig. 3).
Detection of c.719 AG (TPMT*3A & TPMT*3C mutations)
To analyse the c.719 AG polymorphism, a 181-bp
fragment containing nucleotide 719 was amplified with
0.9 ml of 20 mM primer P719NF, a new forward primer
different from that previously described (14, 25), and
0.9 ml of 20 mM primer P719R under the same condi-
tions as those used for the G460A mutation, except that
annealing temperature was 578C. The PCR products
were purified as mentioned above, then 7 ml of each
purified PCR product was digested with 0.2 ml of AccI
10,000 U/ml (New England BioLabs) in 10.8 ml d.d. H2O
and 2 ml buffer 4 (which contained 50 mM potassium
acetate, 20 mM Tris-acetate, 10 mM magnesium acetate,
1 mM DTT, pH 7.9) for 2 h at 378C. Digested products
were separated in 2.5% agarose gel. The c.719 AG
mutation introduces an AccI restriction site in the
amplified fragment and yields fragments of 120 and
60 bp. Wild-type DNA yields an uncleaved fragment of
181 bp (Fig. 4).
The samples with one deficient allele (TPMT*1/*2,
*1/*3C, *1/*3B, *1/*3A) were genotyped as heterozygous
and the samples with two deficient alleles (TPMT*2/*3C,
*2/*3B, *3C/*3B, *2/*3A etc.) were genotyped as homo-
zygous. The samples that carried both the c.460 GA
and c.719AG mutations were named TPMT *3A.
Individuals with heterozygous genotypes in whom both
c.460 GA and c.719AG mutations were detected
in combination with a wild-type nucleotide in the other
allele were presumed to have the TPMT*3A allele and
a wild-type allele, although compound heterozygous
TPMT*3B/TPMT*3C would produce the same genotyp-
ing results. However, TPMT*3B/TPMT*3C genotype is
very rare worldwide.
Statistical analysis
All statistical analyses were performed using the SPSS for
Windows, version 15.0 (SPSS Inc., Chicago, IL). Fre-
quency differences of populations tested for the TPMT
polymorphisms were tested by Pearson’s X2 test. The level
of significance (p value)B0.05 was considered statisti-
cally significant for all analyses.
Results
Genotypic analysis
The TPMT genotypes of the most prevalent muta-
tions worldwide (TPMT*2, TPMT*3A, TPMT*3B, and
TPMT*3C mutations) were determined in an unrelated
Libyan population of 246 healthy adult blood donors
and 50 children with ALL. Overall, there were 170 males
and 126 females. Allele-specific PCR amplification was
used to detect the c.238 GC transversion in exon 5,
while PCR amplification and restriction enzyme digestion
(PCR-RFLP) were used to detect the c.460 GA and
c.719 AG mutations in exon 7 and 10, respectively
(Figs. 3 and 4). Mutant TPMT alleles were found in
3.25% (eight of 246) of the adult Libyan individuals: five
males and three females.
TPMT*3C heterozygous allele was present in five
subjects, with an allele frequency of 1.02% (Table 2).
Fig. 2. Allele-specific PCR-based genotyping assay for the
TPMT c.238 GC mutation. PCR amplification product
from wild-type exon 5 with P2W and P2C primer.
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The second most common mutant allele in Libyan
individuals was TPMT*3A, where three subjects were
heterozygous for TPMT*3A allele, with a frequency of
0.61% making the frequency of total mutant alleles was
1.63% (Table 2).
TPMT*2 (carrying c.238 GC polymorphism) and
TPMT*3B (carrying single nucleotide c.460 GA poly-
morphism alone) were not found in any of the Libyan
individuals. In addition, homozygous or compound het-
erozygous mutant alleles were not detected in any of the
Libyan individuals studied. Table 2 summarises all mutant
alleles found in the Libyan population.
Among the 50 cases of children who had ALL
(majority from Tripoli region; data not shown), no mu-
tant TPMT alleles were detected (Table 2).
Among the 246 adult Libyan subjects, 154 were from
Tripoli population, 54 were from the Yefren population,
and 38 were from the Tawargha population. In the Tripoli
population, three were heterozygous for TPMT*3C allele,
with an allele frequency of 0.97%, and two were hetero-
zygous for TPMT*3A allele, with allele frequency of
0.65%; the frequency of total mutant alleles was 1.62%.
In the Yefren population, only one subject was hetero-
zygous for the TPMT*3C allele, with an allele frequency
of 0.93%, and no other mutant alleles were detected. In
the Tawargha population, one subject was heterozygous for
the TPMT*3C allele and one subject was heterozygous
for the TPMT*3A allele, with an allele frequency of 1.32%
for each allele; the frequency of total mutant alleles was
2.64% (Table 3). Although there are distribution differ-
ences in the TPMT alleles, being higher in Tawargha
(2.64%), lower in Yefren (0.94%) and intermediate in the
Tripoli region (1.62%), no significant relationship was
found between the distribution of the TPMT alleles and
region of origin either among males or females.
Discussion
One of the best examples of the application of pharma-
cogenetics to clinical practice is the genetic polymorph-
ism of the thiopurine S-methyl transferase (TPMT).
Treating TPMT-deficient patients with standard doses
of mercaptopurine (6MP), thioguanine or azathioprine
can be fatal (33), but such patients can be successfully
treated, without severe toxicity, if the dose is properly
adjusted (4, 34). A high degree of concordance has been
demonstrated between TPMT genotype and phenotype
Fig. 3. (a) A 365-bp PCR product of exon 7 using P460F and 460R primers. (b) RFLP-PCR-based genotyping assay for TPMT
c. 460 GA. After complete digestion of the PCR product with MwoI, the mutant allele (Mut: TPMT*3B, *3A) remained as an
uncleaved 365-bp fragment, while the wild allele (W: TPMT*1) yielded 267-bp and 98-bp fragments in a 2.5% agarose gel. Lane 3
shows heterozygous mutant genotype (wt/mt).
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Fig. 4. (a) A 181-bp PCR product amplification of exon 10 using P719NF and P719R primers. (b) RFLP-PCR-based
genotyping assay for TPMT c.719 AG. Example 1: After complete digestion of the PCR product with AccI, the wild allele
(wt: TPMT*1) remained as an uncleaved 181-bp fragment, while the mutant allele (m: TPMT*3C) yielded 120 and 60 bp
fragments in a 2.5% agarose gel. Lane 7 shows heterozygous mutant genotype (wt/mt). (c) RFLP-PCR-based genotyping assay
for TPMT c.719 AG. Example 2: Lane 2 and lane 3 show heterozygous mutant genotypes (wt/mt).
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in Caucasians (13, 35) and the presence of mutant
alleles are predictive of the phenotype, in which hetero-
zygous patients have intermediate activity and homo-
zygous patients have low activity, although variability
can be seen between these groups (1, 22, 36). To date,
of the two strategies used (genotyping and phenotyping)
to identify TPMT-deficient and heterozygous patients,
TPMT genotype can be easily performed.
TPMT activity is known to exhibit genetic polymorph-
ism in most populations studied to date, and the genetic
basis for this inherited trait has been elucidated in most
ethnic groups and races worldwide (Table 4). The present
study is the first to elucidate the genetic basis for this
inherited trait in the Libyan population. The current study
has illustrated that the overall frequency of TPMT alleles
was 1.63% in the Libyan population. That is a relatively
low distribution for this polymorphic gene in Libyans
compared with many ethnic groups such as European,
American and Latin American, Caucasians, as well as black
Africans and African Americans. However, this propor-
tion is higher than detected in South-East Asian, Malay,
and Egyptian populations. TPMT*3C and TPMT*3A
alleles are the most common mutant alleles in the Libyan
population, with an allele frequency of 1.02 and 0.61%,
respectively. On the other hand, TPMT*3B and TPMT*2
were not detected in Libyans. TPMT*2 was found to be
the most prevalent mutation among Brazilians, Turks
and Iranians, whereas TPMT*3A seems the most com-
mon variant in American and European Caucasians. The
TPMT*3C allele is the only mutation found in Japanese,
Thais and South-East Asians (see Table 4).
Although this study was not designed to determine
differences in allele frequency between the different Libyan
populations, determining the presence of polymorphisms
in a population must take into consideration the ethnic
and racial mixture. Thus, it is of the greatest importance
to establish the genetic basis for the TPMT polymorphism
in various populations, including Libyans. Therefore, three
Libyan populations (regions) were chosen according to













TPMT*1 Wild type 98.37 100






TPMT*3B 460GA Ala 154 Thr 0 0
TPMT*3C 719AG Tyr 240 Cyc 1.02 0.0
Total 100 100
aNo. of alleles492; bNo. of alleles100; ALL: acute lymphoblastic
leukaemia.
Table 3. Frequencies of TPMT variant alleles (%) in
different adult Libyan populations according to the region
of origin
%9S.D.
Gender Region N *2 *3A *3C P value
Females Tawargha 46 0.0 2.1792.15 0
Yefren 66 0.0 0.0 0
Tripoli 92 0.0 0 2.1792.15
Total 204 0 0.4990.49 0.9890.69 0.206
Males Tawargha 30 0 0 3.3393.28
Yefren 42 0 0 2.3892.35
Tripoli 216 0 0.9290.65 0.4690.46
Total 288 0 0.6990.49 1.0490.60 0.460
NNo. of alleles, S.D.standard deviation. The level of
significance was set at B0.05.
Table 4. Published frequencies of TPMT variant alleles in
different ethnic groups
Population N *2 *3A *3C References
Caucasian American 564 0.2 3.2 0.2 (27)
African American 496 0.4 0.8 2.4 (27)
Italian 412 0.4 3.9 0.9 (35)
Norwegian 132 _ 3.4 0.3 (37)
Saami Norwegian 388 _ 0.0 3.3 (37)
Bulgarian 626 0.16 2.24 0.16 (20)
Swedish 1,600 0.06 3.75 0.44 (38)
German Caucasian 2,428 0.2 4.4 0.4 (8)
French Caucasian 608 0.7 3.0 0.4 (39)
Chinese 400 0.0 0.0 3.0 (40)
Indian 400 _ 0.0 2.3 (40)
Malay 400 _ 0.5 0.8 (40)
Japanese 302 0.0 0.0 1.6 (41)
South-east Asian 698 0.0 0.0 1.0 (42)
Tibetan 100 0.0 0.0 1.0 (43)
Thai 400 0.0 0.0 9.0 (44)
Mexican 218 0.9 3.2 1.4 (25)
Brazilian 408 2.2 1.5 1.0 (45)
Colombian 280 0.4 3.6 0.0 (24)
Argentinean 294 0.7 3.1 0.0 (46)
Bolivian 230 0.0 6.52 0.0 (43)
Chilean 420 0.24 2.86 0.71 (26)
Turkish 296 2.0 1.0 1.4 (47)
Iranian 254 3.93 0.87 1.57 (48)
Ghanaian 434 0.0 0.0 7.6 (49)
Kenyan 202 0.0 0.0 5.4 (23)
Egyptian 400 _ 0.0 0.3 (29)
Libyan 492 0.0 0.61 1.02 Present study
NNo. of alleles.
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racial and genetic mixing: the Tripoli population, among
whom ethnic and racial mixture is at the highest level,
and the Yefren and Tawargha populations, among whom
ethnic and racial mixture is at the lowest level.
In more detail, the highest mutant alleles were found
in the Tawargha population (2.64%), with equal distribu-
tion for two mutant alleles, TPMT*3A and TPMT*3C,
each at 1.32%. This differs from the findings among black
Africans such as the Ghanaian and Kenyan popula-
tions, among whom only TPMT*3C was detected; since
the Tawargha population are African in origin and have
a black complexion, this might suggest some genetic
mixing with other white Caucasian populations. Surpris-
ingly, the only mutant variant detected in the Yefren
population (Amazigh origins and white complexion) was
TPMT*3C, with an allele frequency of 0.93%, and no
TPMT*3A or TPMT*2 alleles were detected, which are
most common in European Caucasians. However, the
sample sizes for the Tawargha and Yefren populations
were relatively small, and that is why the result for the
distribution of the TPMT alleles in these populations
cannot be taken as decisive. Meanwhile, the frequency
of mutant alleles in the Tripoli population, which is
heterogeneous, was 1.62%, with two mutant alleles,
TPMT*3A (0.65%) and TPMT*3C (0.97%), and this
might be expected owing to the diversity of the Tripoli
population and the very rare distribution of the TPMT*2
mutant allele in most ethnic groups. Thus, TPMT*2 was
not detected in Libyans. This mutation has been found
only in Caucasians and is thought to represent a more
recent allele. In this study, only four mutant alleles,
TPMT*2 and *3A, *3B and*3C, were genotyped in
Libyans. We inferred that the samples in which these
mutant alleles were not detected had the wild-type
TPMT*1. However, it remains a possibility that the
presence of other rare mutant alleles was not detected
in this study.
Regarding the analysis of the children who had ALL,
their records show that nine out of the 50 children had
moderate to severe hematotoxicity from 6MP treatments,
but we were surprised that we did not observe any of the
major TPMT alleles among them (data not shown).
Although we collected the data about the drug therapy,
including the duration of 6MP therapy, maintenance
therapy of 6 MP and hematotoxicity, the absence of any
polymorphism prevents further analyses of the data (data
not shown). This might point to presence of population
specific TPMT alleles that need to be identified in further
studies using more robust techniques, such as sequencing.
Conclusions
In summary, in this study we determined, for the first time,
the frequency of known major TPMT mutant alleles in a
Libyan sample which represented a heterogeneous popu-
lation, reinforcing the importance of taking ethnicity into
account when studying polymorphisms. Therefore, three
Libyan populations (regions) were chosen: the Tawargha
population, in whom the highest total number of mutant
alleles was found (2.64%), with equal distribution of
two mutant alleles (TPMT*3A 1.32% and TPMT*3C
1.32%); the Yefren population, in whom the only mutant
variant detected was TPMT*3C, with an allele frequency
of 0.93%; the Tripoli population, in whom the frequency
of total mutant alleles was 1.62%, with two mutant alleles,
TPMT*3A 0.65% and TPMT*3C 0.97%.
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